Nurx / Prescription Skincare
TRETINOIN, REVIVERX, DARK SPOTS FORMULA
Every concentration, every container size, every price and an explicit statement that the compounded formulas are not FDA approved — all on the page you buy from. It is the disclosure standard this register has been asking nine other companies for. Now read what is in the Dark Spots Formula.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Prescription product — a licensed provider reviews your consultation first. If you are considering the Dark Spots Formula, read the hydrocortisone finding above and agree a stop date before you start.
The verdict
Start with what Nurx gets right, because after nine telehealth reviews it is genuinely startling. On a single page, without a consultation, without a help-centre article, you can read: azelaic acid 10%, niacinamide 4%, tretinoin 0.025/0.05/0.1%, in a 26 ml bottle, for $90 charged as three months at $30. Then the sentence: 'is a compound product. It has not been FDA-approved or evaluated for safety, efficacy, or quality.' Concentration, volume, price and regulatory status, in one place, before you buy.
That is the pattern this register has been documenting the absence of. Musely publishes concentrations in a help centre and never a container size. Alloy publishes an actuator volume and no bottle. Dermatica puts the strength behind a consultation. Nurx publishes all of it on the product listing, alongside single-agent generics at named strengths — tretinoin cream, adapalene 0.3%, hydroquinone 4% — so you can see exactly where the compounded formulas sit against the ordinary ones.
Then read the Dark Spots Formula: azelaic acid 6%, kojic acid 6%, hydroquinone 4%, hydrocortisone 1%, tretinoin 0.05%. Five actives, one of them a topical corticosteroid, sold at $90 for a three-month block on a shipping cycle of one, two or three months. That is the Tri-Luma pattern with two extra actives — and Tri-Luma's own label says it is not for maintenance, that therapy should stop when control is achieved, and that its corticosteroid carries an HPA-axis warning. A three-month billing block is not the same as a three-month course, and nothing on this page says where the course ends.
The rest is a fair trade with clear eyes. Insurance is accepted for acne and rosacea but explicitly not for anti-ageing, melasma, eyelash or hair loss, which the page states plainly. A consultation and support fee sits on top of the medication price, disclosed in the small print. And the tretinoin FAQ frames early irritation as a sign the drug is working — which is the one piece of pharmacological folklore this otherwise disciplined page repeats.
- Every active concentration is printed on the product page, before any consultation.
- Every container size is published — 45 g tube, 26 ml bottle, 1 oz tube, 86 ml bottle.
- Every compounded product carries an explicit 'not FDA-approved or evaluated for safety, efficacy, or quality' statement.
- Spironolactone is listed with a statement that it is not FDA approved for acne and that the company does not endorse that use.
- Single-agent generics at approved strengths are offered alongside the compounds, so the comparison is visible.
- Tretinoin is offered at three strengths, all within the trial range.
- Hydroquinone appears at 4%, the conventional prescription concentration.
- Insurance coverage is stated by indication, including which indications are not covered and why.
- Named side effects and links to full prescribing information on each listing.
- Billing cadence stated: shipped and billed every one, two or three months.
- The Dark Spots Formula contains hydrocortisone 1% with no stated duration, review point or stop date.
- Five actives in one bottle, including a corticosteroid and a recognised sensitiser, with no titration path.
- Kojic acid at 6% has no approved indication and a thin evidence base.
- Azelaic acid appears at 10% and 6%, both below its trialled strengths, without acknowledgement.
- No excipient lists for the compounded formulas, so the vehicle is unknown.
- The consultation and support fee is disclosed but never quantified.
- The tretinoin FAQ frames early irritation and breakouts as a sign the drug is working.
- No pregnancy guidance is given on the skincare listing page for products containing retinoids and hydroquinone.
- Anti-ageing, melasma, lash and hair-loss routes are explicitly not covered by insurance, which makes them the expensive half of the catalogue.
Every active, assessed
- Tretinoin0.025% / 0.05% / 0.1%
Retinoid — the core of both the single-agent cream and the ReviveRx compound
- BENCHMARK
- 0.025% to 0.1% is the acne trial range
- ASSESSMENT
- Three strengths, all inside the trial range, all named on the page, in a stated 45 g tube for the single-agent version. This is the first telehealth service in the register whose retinoid ladder is both published and entirely above the evidence floor.
- Azelaic acid10% (ReviveRx) / 6% (Dark Spots)
Anti-inflammatory, keratinisation, tyrosinase inhibition
- BENCHMARK
- 15% is approved for rosacea, 20% for acne
- ASSESSMENT
- Both figures sit below either approved strength. That is a defensible choice in a multi-active blend, and the numbers are at least printed — but 6% is well under half the lowest concentration azelaic acid has been trialled at, and nothing on the page acknowledges the gap.
- Hydroquinone4%
Tyrosinase inhibitor
- BENCHMARK
- 4% is the conventional prescription strength
- ASSESSMENT
- Correct. It appears both as a standalone 4% cream in a stated 1 oz tube and inside the Dark Spots Formula. This is the right concentration, and the register's contrast is R-01, where the same molecule is compounded at 12%.
- Hydrocortisone1%
Low-potency topical corticosteroid — suppresses irritation from the hydroquinone and tretinoin
- BENCHMARK
- Tri-Luma uses fluocinolone 0.01% and is licensed for short-term use only
- ASSESSMENT
- The reason this product needs a stop date. A facial corticosteroid applied nightly for months produces atrophy, telangiectasia and perioral dermatitis. The approved triple combination that this formula extends carries an explicit limitation of use against maintenance; nothing here does.
- Kojic acid6%
Tyrosinase inhibitor
- BENCHMARK
- No approved concentration; used cosmetically at 1–4%
- ASSESSMENT
- The weakest link in the formula by evidence. Kojic acid has no approved dermatological indication and a thinner trial base than any other active on this page, and 6% is above typical cosmetic use. It is also a recognised contact sensitiser. Printing the number is good; the number itself is unsupported.
- Niacinamide4%
Barrier support, anti-inflammatory, reduces melanosome transfer
- BENCHMARK
- 2–5% is the usual effective range
- ASSESSMENT
- Correctly dosed and sensibly chosen for a formula built around two irritants. No complaint.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| TretinoinRetinoid — the core of both the single-agent cream and the ReviveRx compound | 0.025% / 0.05% / 0.1% | 0.025% to 0.1% is the acne trial range | Three strengths, all inside the trial range, all named on the page, in a stated 45 g tube for the single-agent version. This is the first telehealth service in the register whose retinoid ladder is both published and entirely above the evidence floor. |
| Azelaic acidAnti-inflammatory, keratinisation, tyrosinase inhibition | 10% (ReviveRx) / 6% (Dark Spots) | 15% is approved for rosacea, 20% for acne | Both figures sit below either approved strength. That is a defensible choice in a multi-active blend, and the numbers are at least printed — but 6% is well under half the lowest concentration azelaic acid has been trialled at, and nothing on the page acknowledges the gap. |
| HydroquinoneTyrosinase inhibitor | 4% | 4% is the conventional prescription strength | Correct. It appears both as a standalone 4% cream in a stated 1 oz tube and inside the Dark Spots Formula. This is the right concentration, and the register's contrast is R-01, where the same molecule is compounded at 12%. |
| HydrocortisoneLow-potency topical corticosteroid — suppresses irritation from the hydroquinone and tretinoin | 1% | Tri-Luma uses fluocinolone 0.01% and is licensed for short-term use only | The reason this product needs a stop date. A facial corticosteroid applied nightly for months produces atrophy, telangiectasia and perioral dermatitis. The approved triple combination that this formula extends carries an explicit limitation of use against maintenance; nothing here does. |
| Kojic acidTyrosinase inhibitor | 6% | No approved concentration; used cosmetically at 1–4% | The weakest link in the formula by evidence. Kojic acid has no approved dermatological indication and a thinner trial base than any other active on this page, and 6% is above typical cosmetic use. It is also a recognised contact sensitiser. Printing the number is good; the number itself is unsupported. |
| NiacinamideBarrier support, anti-inflammatory, reduces melanosome transfer | 4% | 2–5% is the usual effective range | Correctly dosed and sensibly chosen for a formula built around two irritants. No complaint. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%70/100
The single-agent generics — tretinoin, adapalene 0.3%, hydroquinone 4% — are approved drugs at approved strengths, which is the strongest position any telehealth service in this register occupies. The compounds are weaker: no trial has tested ReviveRx or the Dark Spots Formula, azelaic acid sits below its trialled strengths in both, and kojic acid at 6% has essentially no clinical base.
- FORMULATION INTEGRITYWEIGHT 20%66/100
Sensible pairings, mostly reasonable concentrations, and container volumes published for every item. Marked down for stacking five actives including a corticosteroid and a sensitiser into a single 26 ml bottle with no titration path and no stated duration, and because no excipient list is published for the compounded formulas.
- DISCLOSUREWEIGHT 15%88/100
The best disclosure of any compounder in this register by a wide margin. Concentrations, container volumes, prices, billing cadence, the FDA-status disclaimer on every compound, named side effects, links to full prescribing information, insurance coverage stated by indication, and the spironolactone listing carrying an explicit statement that it is not FDA approved for acne. Held back only by the additional consultation and support fee being relegated to footnote text, and by no excipient lists.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. A five-active pigment formula containing a retinoid, two acids and a sensitiser is exactly the case where tolerance data would matter most, and neither we nor the company have published any.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. No excipient list is published for the compounded formulas, so even the vehicle type is unknown.
- COST PER APPLICATIONWEIGHT 10%78/100
$90 for a 45 g tube or a 26 ml bottle, with the container size published — so this is one of the few services in the register where cost per application can actually be computed. $15 a month for spironolactone and $30 for tretinoin are reasonable prices, and insurance applies to the acne and rosacea routes. Held back because the consultation and support fee is not quantified anywhere we could find.
What it is
A telehealth prescribing service, part of Thirty Madison, offering both single-agent prescription generics and three in-house compounded formulas for acne, pigmentation, photoageing and hair loss. Medication is shipped and billed every one, two or three months, with a consultation and support fee on top.
The disclosure, first, because it deserves it
Nine telehealth reviews into this register, the recurring finding has been that the concentration exists but is not where you buy. Musely puts it in a help-centre article. Dermatica puts it behind a consultation. Alloy publishes some numbers and omits whichever one would let you check the supply claim. Curology's page describes a formula it will not quantify.
Nurx prints, on the listing page, for every product: the active names, the concentrations, the container volume, the price, the billing cadence, the named side effects, a link to full prescribing information, and — for the compounds — the sentence 'It has not been FDA-approved or evaluated for safety, efficacy, or quality.' It even states, on the spironolactone listing, that the drug is not FDA approved for acne and that the company in no way endorses that use. No other compounder in this register does any of this unprompted.
The container volumes matter more than they look. Because the bottle is 26 ml and the tube is 45 g, cost per application is computable — which it is not for any Musely product, any Alloy product, or most of Dermatica's. That single number is the difference between a price and a specification.
Now read the Dark Spots Formula
Three of these five are the Kligman triple combination, and the approved version of that combination is R-35. Read its limitations of use: not indicated for maintenance, discontinue when control is achieved, melasma usually recurs on stopping. The corticosteroid is why. A low-potency steroid on facial skin night after night thins it, brings up vessels and can produce perioral dermatitis, and the approved product is licensed short-term for exactly that reason.
Nothing on this page states a duration, a review point or a stop date for a formula containing a facial corticosteroid. The default behaviour of a subscription is to continue; the default requirement of this drug class is to stop. This register has made the point about four other companies, and it is the same point here — with the aggravating detail that Nurx has done the harder work of publishing everything else, so the omission is conspicuous rather than systemic.
The kojic acid deserves its own note. It has no approved dermatological indication anywhere, its trial base is thin, and it is a recognised contact allergen. At 6% it sits above typical cosmetic use. Adding it to a formula that already contains the best-evidenced depigmenting agent there is adds sensitisation risk for a benefit nobody has quantified.
The generics are the quiet argument
Alongside the compounds, Nurx lists ordinary prescription drugs at ordinary strengths: tretinoin cream at 0.025%, 0.05% and 0.1% in a 45 g tube; adapalene gel 0.3%; hydroquinone cream 4% in a 1 oz tube; spironolactone at 25, 50 and 100 mg.
Every one of those is an approved product whose evidence you can look up, at a strength that was actually trialled, in a container whose size you know. For most people arriving at a telehealth service wanting 'prescription skincare', the honest answer is that one of those four is what they need, and the compounded formulas are a convenience product layered on top. Nurx is the only service in this register that lets you see both sides of that choice on the same screen.
The one piece of folklore
Many tretinoin users also see increased skin sensitivity, redness, and even breakouts in the first phases of treatment as their skin adjusts to the medication. Fear not—this is generally a sign that tretinoin is doing its job, and these symptoms typically resolve after 6 weeks of treatment.
Nurx skincare treatments page, FAQ
Irritation is a side effect that most people can push through, and the six-week figure is broadly in line with clinical experience. But it is not a sign the drug is working — R-36 records a full-strength tretinoin producing dryness in 4% of users because the vehicle was designed properly, and nobody suggests it worked less well for the other 96%. Framing irritation as evidence of efficacy discourages the two responses that actually help: reduce the frequency, or change the vehicle.
If you are considering it
- Decide first whether you need a compound at all. The single-agent tretinoin, adapalene or hydroquinone listings are approved drugs at approved strengths.
- If acne or rosacea is the indication, use insurance — the page says it is accepted for those and not for the others.
- Ask what the consultation and support fee is before you commit. It is disclosed but not quantified.
- If you are prescribed the Dark Spots Formula, agree a stop date for the hydrocortisone and a plan for what follows.
- Mention any history of contact allergy before accepting kojic acid.
- If you are pregnant or trying, say so — this page has no pregnancy content and half the catalogue is contraindicated.
- Use the published container sizes. 26 ml and 45 g are real numbers and they let you check whether a three-month supply is really three months.
Where we stand
At 74 this is the highest-scoring telehealth compounder in the register, and it earns the position almost entirely on disclosure. The formulas are ordinary and one of them is over-stuffed. But Nurx does the thing every other company here has been asked to do and declined: it tells you what is in the bottle, how big the bottle is, what it costs, and that a regulator never looked at it.
Fix two things and this becomes a recommendation. Put a duration and a review point on the corticosteroid-containing formula. Drop the kojic acid or justify it. Everything else on that page is already the standard the rest of this register should be held to.
The approved triple combination the Dark Spots Formula extends — and the label that says stop.
The same molecule at 12%, with the concentration in a help-centre article.
Why a steroid on rolling billing is the recurring finding in this register.
Who this is for
- Someone who wants a prescription retinoid at a named strength in a stated container, from a service that will tell them the price first.
- Someone with acne or rosacea whose insurance can be used, which is rare in this category.
- Someone who wants to compare a compounded formula against the single-agent generics without leaving the page.
- Someone who values regulatory honesty — this is the only compounder here that states the FDA status of its own products unprompted.
- You want the Dark Spots Formula and are not prepared to agree a stop date for the corticosteroid.
- You react to kojic acid or have a history of contact sensitisation.
- You are pregnant or trying to conceive — retinoids and hydroquinone are both in this catalogue and the page offers no guidance.
- You need to know the vehicle, which is not published for any compounded formula.
- You want a fixed total cost, because the consultation and support fee is unquantified.
Prescription product — a licensed provider reviews your consultation first. If you are considering the Dark Spots Formula, read the hydrocortisone finding above and agree a stop date before you start.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Nurx — Prescription Skincare Treatments page All concentrations and container sizes cited here: tretinoin cream 0.025/0.05/0.1% in a 45 g tube at $90 for three months; adapalene gel 0.3%; hydroquinone cream 4% in a 1 oz tube; spironolactone 25/50/100 mg at $45 for three months; ReviveRx Cream (azelaic acid 10%, niacinamide 4%, tretinoin 0.025/0.05/0.1%) in a 26 ml bottle; Dark Spots Formula (azelaic acid 6%, kojic acid 6%, hydroquinone 4%, hydrocortisone 1%, tretinoin 0.05%) in a 26 ml bottle; RegrowRx Spray (minoxidil 5%, caffeine 0.2%, melatonin 0.1%, tretinoin 0.01%) in an 86 ml bottle. Also the 'not FDA-approved or evaluated for safety, efficacy, or quality' statements, the spironolactone non-endorsement notice, the insurance position by indication, the billing cadence of one, two or three months, the consultation and support fee footnote, and the tretinoin FAQ. Read 2 August 2026.
- S-02FDA-approved labelling — TRI-LUMA cream The limitations of use for the approved triple combination — not indicated for maintenance, discontinue when control is achieved — used here as the comparator for a corticosteroid-containing pigment formula sold without a stated duration.